Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Health, Inc. (NASDAQ:JAGX) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 325,100 shares, a growth of 53.5% from the May 15th total of 211,800 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 0.3 days. Currently, 7.2% of the company’s stock are sold short.

Jaguar Health Stock Up 9.2 %

Shares of JAGX traded up $0.34 on Friday, hitting $4.05. 569,901 shares of the stock traded hands, compared to its average volume of 970,403. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.89 and a quick ratio of 1.39. The business has a 50 day simple moving average of $9.43 and a 200 day simple moving average of $8.12. Jaguar Health has a one year low of $3.07 and a one year high of $43.20.

Jaguar Health (NASDAQ:JAGX) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($3.60) earnings per share (EPS) for the quarter. The company had revenue of $2.35 million during the quarter. Jaguar Health had a negative return on equity of 642.15% and a negative net margin of 377.95%. On average, equities analysts forecast that Jaguar Health will post -5.42 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 1st.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.